Pramlintide and the treatment of diabetes: a review of the data since its introduction (Q33896433)

29 July 2017

1 reference

title

Pramlintide and the treatment of diabetes: a review of the data since its introduction (English)

1 reference

29 July 2017

Lisa M Younk

1

1 reference

29 July 2017

Maia Mikeladze

series ordinal

2

1 reference

29 July 2017

Stephen N Davis

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

13 May 2011

1 reference

Expert Opinion on Pharmacotherapy

29 July 2017

published in

1 reference

29 July 2017

volume

12

1 reference

29 July 2017

issue

9

1 reference

29 July 2017

page(s)

1439-1451

1 reference

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Efficacy and safety of incretin based therapies: clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Amylin release during oral glucose tolerance test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Amylin agonists: a novel approach in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

21 January 2018

Receptor pharmacology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Inhibition of gastric emptying

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Recovery and purification of highly aggregation-prone disulfide-containing peptides: application to islet amyloid polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Tissue expression and secretion of amylin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pramlintide: A new tool in diabetes management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Optimizing treatment success with an amylin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.581663

10.1517/14656566.2011.581663

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference